

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Better Plant Sciences Inc. (the "Issuer").

Trading Symbol: PLNT

Number of Outstanding Listed Securities: 186,503,437 common shares (plus 87,943,513 common shares reserved for issuance in the form of 67,728,185 warrants and 20,215,328 options).

Date: February 4, 2021

Report on Business

1. **Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

In January 2021, the Issuer announced:

- a) its partially owned subsidiary NeonMind Biosciences Inc. (CSE: NEON) listed its common shares on the Frankfurt Stock Exchange under the symbol "6UF"; and
- b) it engaged Pure Product Brokers for sales representation in the U.S., Australia and Japan for its Urban Juve products, commencing immediately.

2. **Provide a general overview and discussion of the activities of management.**

Please see Item 1 above.

3. **Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**

None.

4. **Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.**

None.

5. **Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.**

Please see Item 1 above.

6. **Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.**

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

None.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds (1)
Common Shares	100,000	January 7, 2020: 100,000 common shares issued at a price of \$0.11 per share pursuant to an option exercise	Net proceeds of \$11,000 to be used for general working capital

Common Shares	181,818	January 19, 2020: 181,818 common shares issued at a price of \$0.07 per share pursuant to an option exercise	Net proceeds of \$12,727 to be used for general working capital
Common Shares	80,714	January 26, 2020: 80,714 common shares issued at a price of \$0.08 per share pursuant to an option exercise	Net proceeds of \$6,457 to be used for general working capital
Common Shares	100,000	January 27, 2020: 100,000 common shares issued at a price of \$0.08 per share pursuant to an option exercise	Net proceeds of \$8,000 to be used for general working capital

(1) State aggregate proceeds and intended allocation of proceeds.

15. **Provide details of any loans to or by Related Persons.**

None.

16. **Provide details of any changes in directors, officers or committee members.**

None.

17. **Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

On March 11, 2020, the World Health Organization declared COVID-19 a global pandemic. It has adversely affected global workforces, economies, and financial markets, triggering an economic downturn and is expected to impact many retail businesses. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak nor its effects on the Company's business or operations at this time.

The Issuer implemented travel restrictions for work related travel and imposed self-isolation for employees with symptoms of sickness or returning from international travel. The Issuer also cancelled live multi person events such as in store pop ups and influencer events until further notice.

The Issuer is well-positioned to take advantage of the growing importance placed on physical and mental health and wellbeing, and the rising demand for high-quality, natural products that support this.

The Issuer intends to increase revenues through products that are in high and sustainable consumer demand, drawing on existing, stability-tested formulas to bring these to market under new and existing brands. It has added several hand sanitizer products to its Urban Juve brand, initiated research into topicals that may fight infectious diseases and its partially owned subsidiary, NeonMind Biosciences Inc. has commenced production of its immune boosting mushroom coffee line.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated February 4, 2021.

Penny White
Name of Director or Senior Officer

"Penny White"
Signature

Chief Executive Officer and
President
Official Capacity

Issuer Details Name of Issuer Better Plant Sciences Inc.	For Month End January 2021	Date of Report YY/MM/DD 21/02/04
Issuer Address Suite 200, 1238 Homer Street		
City/Province/Postal Code Vancouver, British Columbia V6B 2Y5	Issuer Fax No. N/A	Issuer Telephone No. 833.514.2677
Contact Name Penny White	Contact Position CEO and President	Contact Telephone No. 833.514.2677
Contact Email Address penny@betterplantsciences.com	Web Site Address www.betterplantsciences.com	